Please login to the form below

Not currently logged in
Email:
Password:

IMI teams with C-Path

Europe’s Innovative Medicines Initiative is to work with US-based C-Path to encourage information sharing 

The Innovative Medicines Initiative (IMI) and the Critical Path Institute (C-Path) have signed a Memorandum of Understanding (MoU) to encourage information sharing between the two organisations.

Europe-based IMI and C-Path, based in the US, share similar objectives focused on accelerating the development of safer, more effective medicines for patients. The organisations bring together scientists and academic institutions, as well as representatives from patient organisations, small and medium-sized companies and regulatory agencies, by forming precompetitive public–private partnerships.

The collaboration will foster increased information sharing regarding each organisation's programmes and create a mechanism to exchange knowledge and develop scientific consensus regarding research and testing methods.

In the key area of drug safety, discussions for such a knowledge exchange are ongoing. The SAFE-T consortium, supported by IMI and the Predictive Safety Testing Consortium led by the Critical Path Institute, are working on the development of new biomarkers to predict, diagnose and monitor drug-induced injury to the liver, the kidneys and the vascular system in the clinical setting. In a statement the organisations said: “Increased collaboration between the international consortia could create important synergies and lead to better results for both projects, for instance, in their interaction with the European and US regulatory authorities EMA and FDA.”

15th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics